Vanda Pharmaceuticals Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Vanda Pharmaceuticals Inc. on April 21, 2006. The filing reports a specific corporate event related to the company's initial public offering (IPO) that occurred on the same date.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a capital structure event rather than operational financial performance.
Material Changes
On April 21, 2006, the underwriters of Vanda Pharmaceuticals' initial public offering exercised an over-allotment option. This action resulted in the purchase of an additional 214,188 shares of the company's common stock.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies beyond the announcement of the over-allotment exercise.
Investor Verification Checklist
- Verify the total number of shares issued following the exercise of the over-allotment option.
- Confirm the final offering price per share to calculate the additional capital raised from the 214,188 shares.
- Review the full press release (Exhibit 99.1) for details on the use of proceeds from the additional shares.